[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644052":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":19,"collaborators":11,"id":21,"slug":22,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":26,"acronym":11,"eligibilityCriteria":27,"healthyVolunteers":23,"sex":28,"minAge":29,"maxAge":11,"enrollmentInfo":30,"targetDuration":11,"studyType":33,"phases":34,"briefSummary":36,"conditions":37,"keywords":11,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":11},{"fullName":5,"class":6},"BrightPath Biotherapeutics Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BP2202","EXPERIMENTAL",null,[13],"Biological: BP2202",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","Intravenous infusion",[9],{"type":20,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100644052","phase-1-a-phase-i-open-label-multicenter-study-to-evaluate-the-safety-and-tolerability-of-bp2202-in-patients-with-relapsedrefractory-multiple-myeloma-100644052",false,"NCT07667868","A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed\u002FRefractory Multiple Myeloma","A Phase I, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n* Diagnosis of Multiple Myeloma with relapsed or refractory disease.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Adequate organ function.\n* Have measurable disease\n\nExclusion Criteria:\n\n* Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of Multiple Myeloma.\n* Known second malignancy that is progressing or requires active treatment or may interfere with study endpoints.","ALL","18 Years",{"count":31,"type":32},18,"ESTIMATED","INTERVENTIONAL",[35],"PHASE1","The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed\u002FRefractory Multiple Myeloma.",[38],"Relapsed\u002FRefractory Multiple Myeloma (RRMM)","NOT_YET_RECRUITING","2026-06-29",{"date":42,"type":43},"2026-07-01","ACTUAL",{"date":45,"type":32},"2026-10-01",{"date":47,"type":32},"2028-12-31",{"name":5,"class":6}]